[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: HGCO19 (COVID-19 vaccine): Novel mRNA-based candidate vaccine candidate; using Spike (S)-protein of the virus as antigen.HGCO19 will be administered IM at day 1 and day 29.Control Intervention1: Placebo: Two doses of 0.5 ml of placebo (buffer); administered Intramuscularly at 4-weeks apart.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: HGCO19 (COVID-19 vaccine): Novel mRNA-based candidate vaccine candidate; using Spike (S)-protein of the virus as antigen.HGCO19 will be administered IM at day 1 and day 29.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Placebo: Two doses of 0.5 ml of placebo (buffer); administered Intramuscularly at 4-weeks apart.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}, {"arm_notes": "administered IM at day 1 and day 29", "treatment_id": 571, "treatment_name": "Hgco19", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "N/A", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: HGCO19 (COVID-19 vaccine): Novel mRNA-based candidate vaccine candidate; using Spike (S)-protein of the virus as antigen.HGCO19 will be administered IM at day 1 and day 29.Control Intervention1: Placebo: Two doses of 0.5 ml of placebo (buffer); administered Intramuscularly at 4-weeks apart.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: HGCO19 (COVID-19 vaccine): Novel mRNA-based candidate vaccine candidate; using Spike (S)-protein of the virus as antigen.HGCO19 will be administered IM at day 1 and day 29.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Control Intervention1: Placebo: Two doses of 0.5 ml of placebo (buffer); administered Intramuscularly at 4-weeks apart.", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]